sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
contraceptives
|
theophylline
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p70
|
NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
|
NSAIDs
|
cyclosporine
|
ADVISE
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s19
|
DDI-DrugBank.d132.s19.p0
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
beta-blockers
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p11
|
Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
|
valdecoxib
|
phenytoin
|
ADVISE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s13
|
DDI-DrugBank.d328.s13.p0
|
Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
|
Vitamin D
|
vitamin D analogues
|
NONE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s13
|
DDI-DrugBank.d98.s13.p0
|
Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
|
quinolones
|
iron
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s7
|
DDI-DrugBank.d562.s7.p0
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
itraconazole
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p4
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
telithromycin
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p9
|
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).
|
glyburide
|
phenformin
|
NONE
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s18
|
DDI-DrugBank.d529.s18.p17
|
Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.
|
Itraconazole
|
coumarin
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s23
|
DDI-DrugBank.d165.s23.p0
|
Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.
|
amyl nitrite
|
alcohol
|
EFFECT
|
Amyl Nitrite_ddi.xml
|
DDI-DrugBank.d56.s0
|
DDI-DrugBank.d56.s0.p0
|
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
fluoxetine
|
paroxetine
|
NONE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s16
|
DDI-DrugBank.d238.s16.p10
|
Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains.
|
clindamycin
|
gentamicin
|
EFFECT
|
15825309.xml
|
DDI-MedLine.d49.s6
|
DDI-MedLine.d49.s6.p0
|
Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
|
Cisapride
|
quinidine
|
ADVISE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s14
|
DDI-DrugBank.d237.s14.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Trileptal
|
Sandimmune
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p407
|
Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.
|
digoxin
|
diltiazem hydrochloride
|
ADVISE
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s20
|
DDI-DrugBank.d565.s20.p2
|
Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
|
baclofen
|
morphine
|
EFFECT
|
Baclofen_ddi.xml
|
DDI-DrugBank.d523.s1
|
DDI-DrugBank.d523.s1.p0
|
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
|
TORADOL
|
fluoxetine
|
EFFECT
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s19
|
DDI-DrugBank.d3.s19.p6
|
Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
|
fluconazole
|
azithromycin
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s8
|
DDI-DrugBank.d53.s8.p2
|
Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
quinolone antibiotics
|
magnesium
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s12
|
DDI-DrugBank.d43.s12.p1
|
However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
|
CELEBREX
|
warfarin
|
ADVISE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s24
|
DDI-DrugBank.d172.s24.p0
|
Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
|
chloroquine
|
ampicillin
|
MECHANISM
|
Chloroquine_ddi.xml
|
DDI-DrugBank.d429.s4
|
DDI-DrugBank.d429.s4.p2
|
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
|
atropine
|
pralidoxime
|
ADVISE
|
Atropine_ddi.xml
|
DDI-DrugBank.d222.s1
|
DDI-DrugBank.d222.s1.p0
|
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
|
BOTOX
|
aminoglycosides
|
ADVISE
|
Botulinum Toxin Type A_ddi.xml
|
DDI-DrugBank.d133.s0
|
DDI-DrugBank.d133.s0.p0
|
However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients.
|
ENBREL
|
methotrexate
|
NONE
|
Etanercept_ddi.xml
|
DDI-DrugBank.d341.s1
|
DDI-DrugBank.d341.s1.p0
|
Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
|
Simulect
|
azathioprine
|
MECHANISM
|
Basiliximab_ddi.xml
|
DDI-DrugBank.d544.s3
|
DDI-DrugBank.d544.s3.p0
|
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
|
estradiol
|
endotoxin
|
EFFECT
|
7600639.xml
|
DDI-MedLine.d39.s2
|
DDI-MedLine.d39.s2.p0
|
Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively. A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
|
magnesium hydroxide
|
fluconazole
|
NONE
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s14
|
DDI-DrugBank.d400.s14.p15
|
Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
|
linezolid
|
serotonergic agents
|
INT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s1
|
DDI-DrugBank.d441.s1.p1
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
selegiline hydrochloride
|
sertraline
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p19
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
Benzthiazide
|
Aleve
|
INT
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p6
|
Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.
|
Phenytoin
|
busulfan
|
MECHANISM
|
Busulfan_ddi.xml
|
DDI-DrugBank.d72.s2
|
DDI-DrugBank.d72.s2.p0
|
BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
|
monoamine oxidase inhibitors
|
adrenergic agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s6
|
DDI-DrugBank.d284.s6.p8
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
phenylbutazone
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p15
|
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
paroxetine
|
fluvoxamine
|
NONE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s16
|
DDI-DrugBank.d238.s16.p14
|
Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
|
ketoconazole
|
aripiprazole
|
MECHANISM
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s9
|
DDI-DrugBank.d509.s9.p3
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
cimetidine
|
sulfamethoxazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p580
|
Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
|
Cyclophosphamide
|
Cerubidine
|
EFFECT
|
Daunorubicin_ddi.xml
|
DDI-DrugBank.d69.s2
|
DDI-DrugBank.d69.s2.p0
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
non-steroidal anti-inflammatory drugs
|
anticoagulants
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p17
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
fenoprofen
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p19
|
Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
|
lorazepam
|
barbiturates
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s0
|
DDI-DrugBank.d18.s0.p3
|
No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
|
digoxin
|
contraceptives
|
NONE
|
Candesartan_ddi.xml
|
DDI-DrugBank.d547.s0
|
DDI-DrugBank.d547.s0.p20
|
Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
|
Allopurinol
|
azathioprine
|
MECHANISM
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s2
|
DDI-DrugBank.d413.s2.p10
|
Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.
|
Anabolic steroids
|
methandrostenolone
|
NONE
|
Fludrocortisone_ddi.xml
|
DDI-DrugBank.d526.s19
|
DDI-DrugBank.d526.s19.p2
|
Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
|
nonsteroidal anti-inflammatory drugs
|
thiazide diuretics
|
EFFECT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s16
|
DDI-DrugBank.d529.s16.p0
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
estrogens
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p5
|
The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
|
dexamethasone
|
Aprepitant
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s11
|
DDI-DrugBank.d382.s11.p0
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
atazanavir
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p5
|
It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
|
dopamine
|
propranolol
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s11
|
DDI-DrugBank.d325.s11.p0
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
nalbuphine
|
Levo-Dromoran
|
ADVISE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p25
|
While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
|
carbamazepine
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s14
|
DDI-DrugBank.d60.s14.p2
|
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
|
ZEBETA
|
disopyramide
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s3
|
DDI-DrugBank.d476.s3.p7
|
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
|
NSAIDs
|
ACE inhibitors
|
EFFECT
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s4
|
DDI-DrugBank.d400.s4.p2
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
Calcidiol
|
fat soluble vitamins
|
NONE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s0
|
DDI-DrugBank.d98.s0.p24
|
Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
|
delavirdine
|
VIDEX
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s14
|
DDI-DrugBank.d43.s14.p4
|
Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
|
beta-adrenergic blockers
|
calcium channel blockers
|
NONE
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s12
|
DDI-DrugBank.d450.s12.p0
|
Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.
|
DIAMOX
|
primidone
|
ADVISE
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s4
|
DDI-DrugBank.d368.s4.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
pimozide
|
triazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p119
|
Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.
|
nafcillin
|
phenobarbital
|
NONE
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s22
|
DDI-DrugBank.d485.s22.p12
|
therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
|
Aprepitant
|
phenytoin
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s34
|
DDI-DrugBank.d382.s34.p2
|
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
|
psychotropic drugs
|
NSAID
|
EFFECT
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s5
|
DDI-DrugBank.d568.s5.p0
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
Magnesium
|
multivitamin preparations
|
NONE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p4
|
However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
|
aspirin
|
Ibandronate
|
ADVISE
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s13
|
DDI-DrugBank.d440.s13.p13
|
However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.
|
carbonic anhydrase inhibitors
|
salicylate
|
INT
|
Brinzolamide_ddi.xml
|
DDI-DrugBank.d497.s2
|
DDI-DrugBank.d497.s2.p0
|
Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
|
amphetamines
|
lithium carbonate
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s19
|
DDI-DrugBank.d236.s19.p2
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
acetaminophen
|
sedative-hypnotics
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p15
|
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
|
1,25(OH)2D3
|
vitamin D
|
NONE
|
7654327.xml
|
DDI-MedLine.d53.s1
|
DDI-MedLine.d53.s1.p2
|
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
|
Macrolide antibiotics
|
lovastatin
|
MECHANISM
|
11197581.xml
|
DDI-MedLine.d25.s12
|
DDI-MedLine.d25.s12.p3
|
Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
|
Mineral oil
|
vitamin D preparations
|
MECHANISM
|
Ergocalciferol_ddi.xml
|
DDI-DrugBank.d471.s0
|
DDI-DrugBank.d471.s0.p1
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
cyclosporine
|
terfenadine
|
NONE
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p34
|
In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.
|
buspirone
|
propranolol
|
NONE
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s5
|
DDI-DrugBank.d463.s5.p1
|
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
|
phenobarbital
|
calcitriol
|
MECHANISM
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s2
|
DDI-DrugBank.d384.s2.p13
|
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
NSAIDs
|
thiazides
|
EFFECT
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s13
|
DDI-DrugBank.d210.s13.p4
|
Propranolol increases hydralazines serum concentrations.
|
Propranolol
|
hydralazine
|
MECHANISM
|
Hydralazine_ddi.xml
|
DDI-DrugBank.d31.s5
|
DDI-DrugBank.d31.s5.p0
|
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
|
Gleevec
|
dihydropyridine calcium channel blockers
|
MECHANISM
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s10
|
DDI-DrugBank.d115.s10.p1
|
Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
|
estrogen
|
contraceptives
|
NONE
|
Ethinyl Estradiol_ddi.xml
|
DDI-DrugBank.d152.s0
|
DDI-DrugBank.d152.s0.p0
|
This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.
|
phenytoin
|
quetiapine
|
MECHANISM
|
11199955.xml
|
DDI-MedLine.d0.s4
|
DDI-MedLine.d0.s4.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
quinine
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p57
|
Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
|
Ketoconazole
|
cyclosporine
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s10
|
DDI-DrugBank.d458.s10.p0
|
For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
|
lovastatin
|
fibrate
|
EFFECT
|
Clofibrate_ddi.xml
|
DDI-DrugBank.d12.s7
|
DDI-DrugBank.d12.s7.p0
|
- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
|
phenytoin
|
reserpine
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s12
|
DDI-DrugBank.d40.s12.p2
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
tricyclic antidepressants
|
quinidine
|
ADVISE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p7
|
It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
|
dantrolene sodium
|
calcium channel blockers
|
ADVISE
|
Dantrolene_ddi.xml
|
DDI-DrugBank.d305.s6
|
DDI-DrugBank.d305.s6.p0
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
celecoxib
|
valsartan
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p47
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
Antihistamines
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p3
|
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
|
imipramine
|
barbiturates
|
MECHANISM
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s5
|
DDI-DrugBank.d77.s5.p2
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
Benzodiazepines
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p9
|
Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.
|
FACTIVE
|
probenecid
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s2
|
DDI-DrugBank.d347.s2.p0
|
Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.
|
CYP3A4
|
amiodarone
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s50
|
DDI-DrugBank.d143.s50.p3
|
- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);
|
tranylcypromine
|
phenelzine
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s4
|
DDI-DrugBank.d521.s4.p23
|
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
|
Sonata
|
ethanol
|
EFFECT
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s1
|
DDI-DrugBank.d324.s1.p4
|
Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.
|
ketoconazole
|
fluconazole
|
NONE
|
Eprosartan_ddi.xml
|
DDI-DrugBank.d525.s2
|
DDI-DrugBank.d525.s2.p3
|
Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
|
almotriptan
|
verapamil
|
MECHANISM
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s8
|
DDI-DrugBank.d299.s8.p3
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
dantrolene
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p8
|
It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.
|
Itraconazole
|
coumarin
|
EFFECT
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s22
|
DDI-DrugBank.d165.s22.p0
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
phenobarbital
|
phenytoin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p533
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
para-aminobenzoic acid
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p7
|
THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
|
HYDROXYZINE
|
NON-NARCOTIC ANALGESICS
|
EFFECT
|
Hydroxyzine_ddi.xml
|
DDI-DrugBank.d308.s0
|
DDI-DrugBank.d308.s0.p2
|
The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
|
CAMPTOSAR
|
antineoplastic agents
|
EFFECT
|
Irinotecan_ddi.xml
|
DDI-DrugBank.d279.s0
|
DDI-DrugBank.d279.s0.p0
|
Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
|
doxapram
|
sympathomimetic
|
EFFECT
|
Doxapram_ddi.xml
|
DDI-DrugBank.d332.s0
|
DDI-DrugBank.d332.s0.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.